Paper9836088
Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.
Kornbluth A. Inflamm Bowel Dis, 1998. Cited by 87 papers, by iCite.
Cite this record
ConductScience Library. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Papers, record 9836088. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9836088
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Crohn Disease | Major topic |
| Drug Approval | Major topic |
| Clinical Trials as Topic | |
| Female | |
| Humans | |
| Infliximab | |
| Male | |
| Treatment Outcome | |
| United States | |
| United States Food and Drug Administration |
Source PubMed
Cited by47
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41908154 | Promising TNF-α inhibitors: Targeting pathogenic TNF-α/TNFR signaling to restore Th17/Treg balance in rheumatoid arthritis. | J Pharm Anal | 2026 | https://conductscience.org/library/papers/41908154 | PubMed |
| 41286500 | Design of minibinder proteins as universal antagonists against canine and human TNFα. | Commun Biol | 2025 | https://conductscience.org/library/papers/41286500 | PubMed |
| 41081067 | Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease. | Prz Gastroenterol | 2025 | https://conductscience.org/library/papers/41081067 | PubMed |
| 40186719 | Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40186719 | PubMed |
| 39532820 | Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations. | Drugs | 2025 | https://conductscience.org/library/papers/39532820 | PubMed |
| 39439890 | Worldwide research trends in Crohn's disease treatment over the past 2 decades: a bibliometric analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39439890 | PubMed |
| 39339221 | Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39339221 | PubMed |
| 38639899 | Surgical management of duodenal crohn's disease. | Langenbecks Arch Surg | 2024 | https://conductscience.org/library/papers/38639899 | PubMed |
| 38534206 | Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development. | Antibodies (Basel) | 2024 | https://conductscience.org/library/papers/38534206 | PubMed |
| 38308773 | Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies. | Indian J Gastroenterol | 2024 | https://conductscience.org/library/papers/38308773 | PubMed |
| 38097975 | The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study. | BMC Gastroenterol | 2023 | https://conductscience.org/library/papers/38097975 | PubMed |
| 37664349 | Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment. | Cureus | 2023 | https://conductscience.org/library/papers/37664349 | PubMed |
| 37288326 | Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study. | Crohns Colitis 360 | 2023 | https://conductscience.org/library/papers/37288326 | PubMed |
| 37274072 | Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/37274072 | PubMed |
| 36836166 | Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. | J Clin Med | 2023 | https://conductscience.org/library/papers/36836166 | PubMed |
| 36807319 | Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease. | Med Sci Monit | 2023 | https://conductscience.org/library/papers/36807319 | PubMed |
| 36704107 | Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36704107 | PubMed |
| 35508955 | Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia. | Intest Res | 2022 | https://conductscience.org/library/papers/35508955 | PubMed |
| 34948292 | Alterations in Kynurenine and NAD+ Salvage Pathways during the Successful Treatment of Inflammatory Bowel Disease Suggest HCAR3 and NNMT as Potential Drug Targets. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34948292 | PubMed |
| 33730998 | Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. | BMC Gastroenterol | 2021 | https://conductscience.org/library/papers/33730998 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9836088
GET https://conductscience.org/api/papers/v1/9836088/cited_by?page=2